A genotype-guided strategy for deciding on antiplatelet agents after PCI does not lead to improvements in long-term ischemic events, according to extended follow-up from TAILOR-PCI. The results are in ...
AMSTERDAM -- Two trials from Asia weighed in on reducing components and duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) but with questionable applicability ...
The results of a large network meta-analysis throw additional support for a paradigm shift in how dual antiplatelet therapy (DAPT) should be maintained after PCI with drug-eluting stents, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback